Advanced Oncotherapy PLC Total Voting Rights (7712K)
August 30 2019 - 12:00PM
UK Regulatory
TIDMAVO
RNS Number : 7712K
Advanced Oncotherapy PLC
30 August 2019
30 August 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Total Voting Rights
Advanced Oncotherapy plc (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that the Company's issued share capital as at the date of
this announcement comprises 230,226,094 ordinary shares of 25p
each, with one voting right per share ("Ordinary Shares"). The
Company does not hold any ordinary shares in treasury and therefore
the total number of Ordinary Shares with voting rights in the
Company is 230,226,094.
The above figure of 230,226,094 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
& Joint Broker)
Nick Athanas / Liz Kirchner / Tel: +44 20 7601 6100
Nicholas Chambers
Stifel Nicolaus Europe (Joint
Broker)
Jonathan Senior Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 54 1 893 / Mob: +44
7876 741 001
About Advanced Oncotherapy Plc
Advanced Oncotherapy is a provider of particle therapy in the
treatment of cancer, which harnesses the very best in modern
technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva,
focuses on the development of a proprietary proton accelerator -
LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates
protons to the energy levels achieved in legacy machines but in a
compact and truly modular unit, offering significant cost
advantages. LIGHT also delivers proton beams in a way that
facilitates greater precision and electronic control, which are not
achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology, offering better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton or particle therapy and
actively seeks working relationships with providers of these
innovative technologies. Through these relationships, the Company
will remain the prime provider of cutting edge, cost-effective
systems for particle therapy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREALPEDDXNEFF
(END) Dow Jones Newswires
August 30, 2019 12:00 ET (16:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024